A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.

Trial Details

NCT ID
NCT06868485
Phase
PHASE2
Sponsor
Wayshine Biopharm, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • WSD0922-FU Tablets, Dose level A
  • WSD0922-FU Tablets, Dose level B
Locations (sample)
  • Oxnard, California, United States|34.1975,-119.17705
  • Weston, Florida, United States|26.10037,-80.39977
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Manahawkin, New Jersey, United States|39.6954,-74.25875
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling and analyses.
  • Male or female aged ≥18 years old.
  • Histological or cytological confirmation diagnosis of NSCLC.
  • Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →